IMS 2022 | Session highlights: disease monitoring in multiple myeloma
Saad Usmani
• 25 Aug 2022
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of the abstracts presented during the disease monitoring session at the 2022 IMS meeting. Dr Usmani also shares some insights into the E-PRISM trial (NCT02279394) and updates from the FORTE trial (NCT02203643) which were presented, and implications of these studies in clinical practice. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
